index: hide

#### PD-L1 ≥1%
- First-line therapy*
  - Pembrolizumab {gen.nscl.principles.i.'24},{gen.nscl.principles.i.'25},{gen.nscl.principles.i.'26}
  - (Carboplatin or cisplatin)/pemetrexed/pembrolizumab (non-squamous) {gen.nscl.principles.i.'27}
  - Carboplatin/paclitaxel/bevacizumab/atezolizumab (nonsquamous) {gen.nscl.principles.i.'28}
  - (Carboplatin or cisplatin)/(paclitaxel or albumin-bound paclitaxel)/pembrolizumab (squamous) {gen.nscl.principles.i.'29}

\* Continuation maintenance refers to the use of at least one of the agents given in first line, beyond 4–6 cycles, in the absence of disease progression.
